South Korea Genomics Market (2025-2030)
The South Korea Genomics Market was valued at $11417.7 Million in 2025 and projected to reach to $21712.3 Million by 2030, representing a compound annual growth rate of CAGR 13.7%. South Korea's genomics sequencing market is positioned for substantial growth, expanding from $11,417.7 million in 2025 to $21,712.3 million by 2030.
South Korea Genomics Market Trends and Insights
- Sequencing technologies are driving innovation across clinical diagnostics, research, and personalized medicine applications.
- The expansion of Sequencing is fueled by declining costs, increased adoption of next-generation sequencing (NGS) platforms, and growing demand for genomic data in precision healthcare.
- Sequencing continues to dominate the genomics landscape as healthcare providers and research institutions invest heavily in advanced sequencing infrastructure and capabilities. The Sequencing segment is experiencing accelerated growth due to technological breakthroughs and expanding clinical applications.
- Sequencing methodologies are becoming integral to cancer genomics, rare disease diagnosis, and pharmacogenomics.
- Between 2025 and 2030, Sequencing is expected to capture increasing market share as automation and data analytics enhance the efficiency of sequencing workflows.
- Sequencing adoption is particularly strong in developed markets, though emerging economies are rapidly scaling sequencing capabilities to support precision medicine initiatives..
Key Market Statistics
- CAGR (2025-2030) CAGR 13.7%
- Market Size, 2025 ~USD 11417.7 Million
- Forecast, 2030 ~USD 21712.3 Million
- Country South Korea
South Korea Genomics Market Overview
Rapid Market Expansion :
South Korea's genomics market is experiencing accelerated growth at 13.7% CAGR, outpacing the global average of 12.6%, driven by government investments in precision medicine and biotech infrastructure development.
NGS Adoption Leadership :
South Korea leads in next-generation sequencing adoption across Asia-Pacific, with major hospitals and research institutions integrating NGS for clinical diagnostics, cancer genomics, and rare disease identification.
Government Support & Funding :
The Korean government's genomics roadmap and substantial R&D funding through institutions like KNIH and KRIBB are accelerating sequencing technology deployment and clinical implementation across the healthcare system.
Personalized Medicine Integration :
South Korean healthcare providers are rapidly adopting genomic sequencing for personalized treatment planning, particularly in oncology and pharmacogenomics, creating strong demand for sequencing services and platforms.
South Korea Genomics Market Dynamics
- This trajectory reflects the country's advanced healthcare infrastructure, strong biotech ecosystem, and government commitment to precision medicine initiatives.
- The market benefits from declining sequencing costs, increasing clinical adoption, and growing demand for personalized treatment approaches. Key drivers include rising cancer incidence requiring genomic profiling, expanding newborn screening programs, and increased investment in genomic research facilities.
- South Korea's aging population and emphasis on preventive healthcare further accelerate sequencing adoption.
- Strategic partnerships between local biotech firms and international genomics companies are enhancing market accessibility and technological advancement across clinical and research sectors..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Sequencing market is valued at $11.4B in 2025 and expected to reach $21.7B by 2030, growing at a 13.7% CAGR.
- Sequencing technologies are becoming essential for clinical diagnostics, cancer genomics, and personalized medicine applications.
- Declining sequencing costs and NGS platform adoption are primary drivers accelerating Sequencing market expansion.
- Sequencing adoption is accelerating in both developed and emerging markets as precision medicine becomes standard clinical practice.
Genomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.6% from 2025 to 2030 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 47.01 (2025) |
| Revenue Forecast (Billions) | ~USD 85.09 (2030) |
| Segments Covered | Offering, Type, Technology, End User, Study Type, Application |
South Korea Genomics Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioinformatics Services
- Bioinformatics Tools
- Cancer Diagnostics
- Genomic Profiling & Sequencing Services
- Infectious Disease Diagnostics
- Instruments
- Other Diagnostic Applications
- Reagents, Kits, And Consumables
- Reproductive Health Diagnostics
- Sample Preparation & Library Preparation Services
By Technology
- Flow Cytometry
- Gene Editing
- In Situ Hybridization
- Microarrays
- Other Technologies
- Pcr
- Sequencing
By End User
- Academic & Research Institutes
- Cros
- Hospitals, Diagnostic Laboratories, And Clinics
- Other End Users
- Pharmaceutical & Biotechnology Companies
By Study Type
- Biomarker Discovery
- Epigenomics
- Functional Genomics
- Other Study Types
- Pathway Analysis
By Application
- Agriculture & Animal Research
- Diagnostics
- Drug Discovery & Development
- Other Applications
Target Audience
- Genomics Equipment Manufacturers : Sequencing platform vendors and diagnostic equipment providers need South Korea-specific market data to assess demand, identify hospital procurement trends, and develop localized sales strategies for this high-growth Asian market.
- Clinical Diagnostic Companies : Diagnostic service providers require detailed insights into South Korean clinical adoption patterns, reimbursement policies, and competitive landscape to position genomic testing services and expand market share.
- Biotech & Pharmaceutical Firms : Companies developing precision medicine solutions and targeted therapies need South Korea market intelligence to understand genomic profiling adoption, clinical trial opportunities, and personalized treatment implementation.
- Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in South Korea's biotech and genomics sectors require market sizing, growth projections, and competitive analysis to support investment decision-making and portfolio strategy.
- Research Institutions & Academic Centers : Universities and research organizations need market data on genomics infrastructure development, government funding trends, and technology adoption patterns to inform research priorities and collaboration opportunities in South Korea.
Key Companies in the South Korea Genomics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABCAM PLC | United Kingdom | Private Company | Reagents (antibodies, proteins, peptides, biochemicals),Kits (conjugation, cellular activity, pathway tools, immunoassays),Instruments and tools-adjacent products, |
| AFFYMETRIX INC | United States | Private Company | Reagents,Kits,Instruments, |
| BECKMAN COULTER | United States | Private Company | Instruments (flow cytometers, centrifuges, capillary electrophoresis, liquid handlers, analyzers),Reagents & Kits (sample prep, library construction, single-cell PCR, immunoassay),Genome Profiling & Genomic Services, |
| CEPHEID INC. | United States | Private Company | Instruments (GeneXpert, SmartCycler),Reagents & Kits (Xpert tests and related consumables),Services (Genome profiling, bioinformatics, support), |
| CORNING, INC. | United States | Public Company | Reagents and Kits,Instruments and Lab Equipment,Labware and Specialty Surfaces for Genomics, |
| DECODE GENETICS | Iceland | Private Company | Reagents,Kits,Instruments, |
| GENOMIC HEALTH INC | United States | Private Company | Genomic-based diagnostic services (oncology),Genome profiling services beyond core oncology,Bioinformatics and data-related services, |
| UNILABS | Switzerland | Private Company | Reagents,Kits,Instruments, |
| MAXCYTE, INC | United States | Public Company | Instruments (ExPERT ATx, STx, GTx, VLx),Consumables (Processing Assemblies, buffers, accessories),Licensing and technology access, |
| DANAHER CORPORATION | United States | Public Company | Reagents and Kits,Instruments (Sequencing-adjacent, PCR, Flow Cytometry, Sample Prep),Services (Genome Profiling, Bioinformatics, Custom Development), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Instruments (sequencing-adjacent, PCR, flow cytometry, ISH platforms),Reagents and Kits,Genomics Services (Genome Profiling, CDMO, and Lab Services), |
| REVVITY | United States | Public Company | Reagents & Kits,Instruments,Genome Profiling Services, |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | United States | Public Company | Reagents,Kits,Instruments, |
| IQVIA INC. | United States | Public Company | Genomics Services – Genome Profiling & Central Labs,Bioinformatics & Real-World Genomics Analytics,Genomics-Enabled Clinical Research Services, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Reagents,Kits,Instruments, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Reagents,Kits,Instruments, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Reagents,Kits,Instruments, |
| PACBIO | United States | Public Company | Instruments (Revio, Sequel, Vega, Onso),Reagents & Kits (SMRT cells, prep, binding, sequencing kits),Services (Genome profiling, bioinformatics and related), |
| OXFORD NANOPORE TECHNOLOGIES PLC. | United Kingdom | Public Company | Instruments (MinION, GridION, PromethION family),Reagents & Kits,Genome Profiling & Sequencing Services, |
| TAKARA BIO INC. | Japan | Private Company | Reagents,Kits,Instruments, |
ABCAM PLC
Abcam PLC is a United Kingdom-based private company founded in 1998 with 1,760 employees that develops and supplies research reagents and tools for the life sciences industry.
AFFYMETRIX INC
Affymetrix Inc. is a United States-based private company founded in 1991 with 1,150 employees focused on molecular biology and genomic analysis technologies.
BECKMAN COULTER
Beckman Coulter is a United States-based private company founded in 1935 with 11,900 employees that manufactures and distributes laboratory instruments and diagnostic equipment.
CEPHEID INC.
Cepheid Inc. is a United States-based private company founded in 1996 with 1,700 employees that develops molecular diagnostic systems and point-of-care testing solutions.
CORNING, INC.
Corning, Inc. is a United States-based public company founded in 1851 with 67,200 employees that manufactures specialty glass, ceramics, and laboratory equipment.
DECODE GENETICS
deCODE Genetics is an Iceland-based private company founded in 1996 with 331 employees focused on genomic research and genetic analysis.
GENOMIC HEALTH INC
Genomic Health Inc. is a United States-based private company founded in 2000 with 829 employees specializing in genomic-based diagnostic testing.
UNILABS
Unilabs is a Switzerland-based private company founded in 1987 with 1,897 employees providing clinical laboratory and diagnostic testing services.
MAXCYTE, INC
MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering and electroporation technologies.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating a diversified portfolio of businesses including life sciences and diagnostics.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees manufacturing analytical instruments and life sciences equipment.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees providing analytical instruments and life sciences solutions.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Laboratory Corporation of America Holdings is a United States-based public company founded in 1995 with 66,385 employees operating one of the largest clinical laboratory networks.
IQVIA INC.
IQVIA Inc. is a United States-based public company with 93,000 employees providing clinical research, data analytics, and technology solutions to the pharmaceutical and healthcare industries.
CHARLES RIVER LABORATORIES
Charles River Laboratories is a United States-based public company founded in 1947 with 19,000 employees providing preclinical and clinical laboratory services for drug development.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees manufacturing and distributing life science research and clinical diagnostic products.
EUROFINS SCIENTIFIC
Eurofins Scientific is a Luxembourg-based public company founded in 1987 with 65,694 employees providing laboratory testing and analytical services across multiple industries.
PACBIO
PacBio is a United States-based public company founded in 2000 with 485 employees developing long-read DNA sequencing technologies.
OXFORD NANOPORE TECHNOLOGIES PLC.
Oxford Nanopore Technologies PLC. is a United Kingdom-based public company founded in 2005 with 1,316 employees specializing in nanopore-based DNA and RNA sequencing technologies.
TAKARA BIO INC.
Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees providing molecular biology reagents and biotechnology products.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation ($11.4B in 2025) and 5-year forecast data specific to South Korea's genomics sequencing sector, enabling accurate investment planning and competitive positioning in this high-growth market.
- Regional Competitive Intelligence : Understand South Korea's market dynamics relative to global trends (13.7% vs 12.6% CAGR), identify local competitors, and assess market saturation levels to inform market entry or expansion strategies.
- Government Policy & Regulatory Insights : Access analysis of South Korean government initiatives, precision medicine roadmaps, and regulatory frameworks driving sequencing adoption in clinical settings and research institutions across the healthcare system.
- Clinical Adoption Trends : Gain detailed insights into NGS implementation patterns across South Korean hospitals, diagnostic centers, and research facilities, including adoption rates for cancer genomics, rare disease screening, and pharmacogenomics applications.
- Strategic Partnership Opportunities : Identify key stakeholders, biotech companies, healthcare providers, and research institutions in South Korea's genomics ecosystem to inform partnership development, distribution agreements, and market collaboration strategies.
Frequently asked questions
What is the projected market size for Sequencing in 2030?
Sequencing is projected to reach $21,712.3 million by 2030, up from $11,417.7 million in 2025.
What is the CAGR for the Sequencing segment?
Sequencing is expected to grow at a compound annual growth rate (CAGR) of 13.7% from 2025 to 2030.
What are the main drivers of Sequencing market growth?
Sequencing growth is driven by declining technology costs, increased NGS platform adoption, expanding clinical applications, and rising demand for precision medicine solutions.
Which applications are driving Sequencing adoption?
Sequencing is increasingly adopted in cancer genomics, rare disease diagnosis, pharmacogenomics, and clinical diagnostics across healthcare systems.
How is Sequencing adoption distributed geographically?
Sequencing adoption is strongest in developed markets, while emerging economies are rapidly scaling sequencing infrastructure to support precision medicine initiatives.
RESEARCH METHODOLOGY
This research study utilized extensive secondary sources, directories, and databases to identify and collect valuable information for analyzing the global genomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to gather and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive, technical, market-oriented, and commercial study of the genomics market. The secondary sources used for this study include Nucleic Acids Research, Genome Biology, the International Journal of Genomics, the National Human Genome Research Institute (NHGRI), the International Chromosome and Genome Society (ICGS), Genome Canada, the European Society of Human Genetics (ESHG), Genomics England, Genome British Columbia, Beijing Institute of Genomics, the Centre for Cellular & Molecular Biology (CCMB), São Paulo Research Foundation (FAPESP), Nature Reviews Genetics, Nature Methods, the Biotechnology and Biological Sciences Research Council (BBSRC), the Organisation for Economic Co-operation and Development (OECD), Genome Research, the National Cancer Institute (NCI), the European Medicines Agency (EMA), the Population Health Research Institute (PHRI), PubMed, World Bank, the World Health Organization (WHO), Eurostat, and Factiva; research journals; corporate filings, such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, and professional associations, among others. These sources were also utilized to gather key information about major players, market classification, and segmentation, as well as industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
After acquiring foundational knowledge about the global genomics market through secondary research, extensive primary research was conducted. Multiple interviews were held with market experts from the demand side, including representatives from academic & research institutes, hospitals, clinics & diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. Additionally, experts from the supply side were interviewed, including C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
These interviews spanned six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while the remaining 30% were with demand-side participants. The primary data was collected through various methods, including questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the genomics market. These methods were also used extensively to estimate the size of various market segments. The research methodology used to estimate the market size includes the following:
After determining the overall market size through the estimation process, the total market was divided into several segments and subsegments.
Genomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Genomics is a branch of molecular biology that involves the study of the structure, function, evolution, and mapping of genomes. It applies the techniques of genetics, molecular biology, and bioinformatics to sequence, assemble, and analyze the function and structure of the genome of a selected organism for analysis. Genomics is widely used in diagnostics, drug discovery and development, animal and agricultural research, forensics, and aquaculture research, among others.
Key Stakeholders
- Genomics Equipment and Consumable Manufacturing Companies
- Genomics Instrument/System Manufacturing Companies
- Suppliers and Distributors of Genomic Instruments/Systems, Consumables, and Services
- Hospitals, Diagnostic Centers, and Medical Colleges
- Research Institutes
- Hospitals and Academic Medical Centers (AMCs)
- Government Bodies/Municipal Corporations
- Business Research Firms
- Venture Capitalists
- Pharmaceutical and Biopharmaceutical Companies
Report Objectives
- To define, describe, and forecast the genomics market based on offering, product type, service type, product by technology, application, end user by product, end user by service, and region, in terms of value
- To forecast the size of the market segments with respect to six main regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa, in terms of value
- To provide detailed information regarding the major factors influencing market growth, such as drivers, restraints, opportunities, and challenges
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall genomics market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile key players in the genomics market and comprehensively analyze their product and service portfolios, market positions, and core competencies
- To track and analyze competitive developments in the genomics market, such as acquisitions, product & service launches, expansions, agreements, partnerships, and collaborations
- To benchmark players within the genomics market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product & service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific genomics market into countries
- A further breakdown of the Rest of Europe genomics market into countries
- A further breakdown of the Rest of Latin America genomics market into countries
- A further breakdown of the Rest of Middle East genomics market into countries
Get the Full Genomics Market Report
Full forecast, segment splits, and company analysis for all Genomics Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report